Related by context. All words. (Click for frequent words.) 76 median PFS 72 progression TTP 72 Free Survival PFS 69 plus dexamethasone 69 chlorambucil 69 FOLFIRI 68 FOLFOX 68 mRCC 68 evaluable 68 Median progression 68 evaluable patients 68 Median PFS 68 FOLFOX4 67 low dose cytarabine 66 docetaxel 66 gemcitabine 66 Median survival 66 tumor progression TTP 66 dacarbazine 66 metastatic renal cell carcinoma 65 plus prednisone 65 advanced NSCLC 65 docetaxel chemotherapy 65 patients evaluable 65 trastuzumab 65 CR nPR 65 bevacizumab 64 Kaplan Meier analysis 64 mitoxantrone 64 carboplatin 64 heavily pretreated 64 carboplatin paclitaxel 64 vandetanib 64 VELCADE melphalan 64 axitinib 64 recurrent GBM 64 secondary endpoint 64 peginterferon alfa 2a 64 RECIST criteria 64 decitabine 64 VcMP 63 Fludara 63 biochemical recurrence 63 Folfox 63 XELOX 63 bortezomib 63 KRAS mutant tumors 63 % CI #.#-#.# [003] 63 pegylated interferon alfa 2b 63 erlotinib 63 standard chemotherapy regimen 63 achieved ACR# 63 CCyR 63 locoregional 63 prospectively defined 63 tumor shrinkage 63 mCRC 63 mCRC patients 62 PREZISTA r 62 chemoradiation 62 mg QD 62 pemetrexed 62 placebo dexamethasone 62 virologic response 62 mg kg dose 62 FOLFIRI alone 62 sunitinib 62 dose dexamethasone 62 sustained virologic response 62 CR CRu 62 HER2 positive metastatic breast 62 KRAS wild 62 relapsed refractory multiple myeloma 62 plus gemcitabine 62 recurrent NSCLC 62 bosentan 62 KRAS mutations occur 62 mcg albinterferon alfa 2b 62 Scale EDSS 62 annualized relapse 62 adalimumab 62 remission CR 62 neoadjuvant chemotherapy 62 rituximab 62 partial remissions 61 5-FU/LV 61 ACR# response 61 disease progression TTP 61 metastatic castration resistant 61 Partial Responses 61 neoadjuvant therapy 61 preoperative chemotherapy 61 cytogenetic response 61 melphalan prednisone 61 glufosfamide 61 biochemical relapse 61 tiotropium 61 azacitidine 61 5 FU 61 Doxil ® 61 cetuximab 61 Secondary endpoints include 61 FluCAM 61 squamous histology 61 low dose dexamethasone 61 plus ribavirin 61 cisplatin chemotherapy 61 pegylated liposomal doxorubicin 61 pCR 61 metastatic HRPC 61 Response Evaluation Criteria 61 mg BID 61 5FU 61 peginterferon 61 adjuvant therapy 61 oblimersen 61 R# #mg BID 61 resected pancreatic cancer 60 complete cytogenetic 60 capecitabine 60 8mg/kg 60 APTIVUS r 60 relapsed MM 60 HBeAg seroconversion 60 gefitinib 60 telaprevir dosed 60 temsirolimus 60 recurrent glioblastoma multiforme 60 Kaplan Meier estimate 60 primary endpoint 60 locoregional disease 60 vinorelbine 60 mcg kg 60 neurologic progression 60 achieved CCyR 60 imatinib 60 gemcitabine chemotherapy 60 Secondary endpoints 60 #mg QD [002] 60 secondary efficacy endpoints 60 temozolomide 60 Flu Cy 60 sustained virological response 60 heavily pretreated patients 60 adjuvant chemotherapy 60 clodronate 60 IFN alfa 60 metastatic RCC 60 RECIST 60 relapsing multiple sclerosis 60 fluorouracil 60 achieved sustained virological 60 unresectable 60 CIMZIA ™ 60 cisplatin vinorelbine 60 postoperative chemotherapy 60 sipuleucel T 60 monotherapy 60 metastatic colorectal cancer 60 achieved PASI 60 gemcitabine carboplatin 60 evaluable subjects 60 dose cohorts 60 refractory multiple myeloma 60 sorafenib 60 locoregional recurrence 60 stage IIIb IV 60 Secondary endpoints included 60 neoadjuvant 59 PSADT 59 chemoradiotherapy 59 bendamustine 59 dasatinib 59 mg ustekinumab 59 brain metastases 59 CRp 59 sorafenib Nexavar ® 59 LVEF 59 % CI #.#-#.# [007] 59 topotecan 59 distant metastasis 59 mcg dose 59 endoscopic remission 59 plasma uric acid 59 estramustine 59 complete remissions 59 ACTEMRA TM 59 p = #.# [004] 59 CIMZIA TM 59 FOLFOX regimen 59 castration resistant prostate cancer 59 cEVR 59 FOLFOX4 alone 59 imatinib therapy 59 HBeAg positive patients 59 comparator arm 59 Ceplene/IL-2 59 bortezomib refractory 59 liver metastases 59 certolizumab 59 locoregional control 59 achieve sustained virologic 59 undetectable HCV RNA 59 metastatic GIST 59 pomalidomide 59 melphalan 59 pegylated interferon 59 interferon alfa 2a 59 baminercept 59 HCV genotype 1 59 follicular NHL 59 lung metastases 59 composite endpoint 59 cabazitaxel 59 relapsed CLL 59 lumbar spine BMD 59 mutated KRAS 59 abiraterone acetate 59 SVR# 59 dacarbazine chemotherapy 59 confirmed CCyR 59 lintuzumab 59 XIENCE V PROMUS Stent 59 RECIST Response Evaluation Criteria 59 NATRECOR R 58 lopinavir r 58 HbA1c levels 58 randomized Phase III 58 remission induction 58 sorafenib Nexavar 58 cancer mCRC 58 5 fluorouracil 58 definite stent thrombosis 58 mucosal healing 58 ribavirin RBV 58 surrogate endpoint 58 P = .# 58 DAS# remission 58 #mg BID [001] 58 octreotide LAR 58 pegylated interferon alpha 58 HCV genotype 58 BEACOPP 58 fludarabine 58 sunitinib malate 58 YERVOY 58 Halaven 58 tumor recurrence 58 viral kinetic 58 dacarbazine DTIC 58 prostate cancer CRPC 58 KRAS status 58 lenalidomide 58 metastatic CRC 58 peg IFN 58 TACE 58 TAXUS Express Stent 58 desvenlafaxine succinate 58 infliximab 58 EDSS scores 58 dosing cohorts 58 plus methotrexate 58 #mg/m# [002] 58 refractory AML 58 EBRT 58 diagnosed multiple myeloma 58 afatinib 58 Amrubicin 58 tipranavir r 58 CYPHER ® Stent 58 sirolimus eluting stent 58 refractory NSCLC 58 achieved sustained virologic 58 rapid virologic response 58 splenectomized patients 58 CMV disease 58 mapatumumab 58 anastrozole 58 nab paclitaxel 58 Peg IFN 58 VIDAZA 58 #mg BID [003] 58 virologic failure 58 mitoxantrone plus 58 IFN α 58 prespecified 58 complete cytogenetic response 58 EDSS score 58 HCV RNA 58 peginterferon alfa 2b 58 adefovir 58 EGFR mutation positive 58 DAPT 58 metastatic melanoma 58 methotrexate monotherapy 58 virologic 58 Operative mortality 58 PegIFN RBV 58 nodular partial response 57 FOLFOX6 57 primary efficacy endpoint 57 chronic lymphocytic leukemia CLL 57 etanercept 57 microbiological eradication 57 paclitaxel chemotherapy 57 refractory CTCL 57 chemotherapy regimen 57 Elitek 57 posaconazole 57 EURIDIS 57 prior chemotherapy regimens 57 RRMS patients 57 daunorubicin 57 relapsed refractory 57 % Confidence Interval 57 alfa 2a 57 cisplatin 57 placebo p = 57 Solid Tumors criteria 57 HRPC 57 mg/m2 dose 57 PRECiSE 57 resistant ovarian cancer 57 cilengitide 57 infliximab monotherapy 57 FOLOTYN 57 ACR# [002] 57 noninferiority 57 liver histology 57 interferon alfa 57 IMGN# 57 NSCLC 57 antitumor activity 57 pharmacokinetics PK 57 teriflunomide 57 secondary endpoints 57 APPRAISE 57 undetectable viral load 57 FOLPI 57 tamoxifen therapy 57 platinum refractory 57 stage IIIB 57 response CCyR 57 MabCampath 57 trabectedin 57 oral Hycamtin 57 docetaxel Taxotere 57 4mg/kg 57 Taxus Stent 57 IU ml 57 relapsed SCLC 57 CRu 57 untreated multiple myeloma 57 STELARA 57 azathioprine 57 mCi kg 57 eribulin mesylate 57 viral kinetics 57 eribulin 57 ALND 57 lamivudine monotherapy 57 EGFr expressing metastatic colorectal 57 fondaparinux 57 plus MTX 57 paclitaxel carboplatin 57 null responders 57 leukemia AML 57 HBeAg negative patients 57 cytogenetic responses 57 LEXIVA r 57 Pharmacokinetics PK 57 galiximab 57 receiving VICTRELIS 57 -#.# log# 57 irinotecan cisplatin 57 DMARD 57 mycophenolate mofetil 57 Hazard Ratio 57 treatment naive genotype 57 custirsen 57 metastatic renal cell 57 biliary tract cancer 57 naïve HCV 57 5-fluorouracil/leucovorin 57 confidence interval CI 57 oxaliplatin 57 metastatic prostate cancer 57 tocilizumab 57 Kaplan Meier estimates 56 rindopepimut 56 Bezielle 56 EGFR expressing mCRC 56 lymphocytosis 56 PASI scores 56 detectable HCV RNA 56 postintervention 56 erlotinib Tarceva ® 56 clinically localized prostate 56 amrubicin 56 RGT arm 56 chemotherapy regimens 56 HER2 negative 56 nonsquamous 56 gemcitabine Gemzar 56 adjuvant tamoxifen 56 hepatic metastases 56 gemcitabine cisplatin 56 everolimus eluting stents 56 ACR Pedi 56 IIIB NSCLC 56 WBRT alone 56 Solid Tumors RECIST 56 Crohn Disease Activity 56 indolent NHL 56 infusional 5-FU/LV 56 Vectibix 56 relapsed GBM 56 serum phosphorus 56 crizotinib PF # 56 metastatic disease 56 FLT3 ITD 56 biologic therapy 56 PROSTVAC TM 56 oral ridaforolimus 56 minimally symptomatic 56 morphometric vertebral fractures 56 distant metastases 56 pancreatic adenocarcinoma 56 BRIM2 56 mg/m2 56 adalimumab Humira 56 docetaxel prednisone 56 CIMZIA TM certolizumab pegol 56 nonfatal MI 56 preintervention 56 hormone refractory prostate cancer 56 EFAPROXYN 56 Pegasys ® 56 Expanded Disability Status 56 TORISEL 56 adecatumumab 56 TLUS 56 lamivudine 56 dose cohort 56 methotrexate MTX 56 chemotherapy gemcitabine 56 #mg/m# [001] 56 Taxotere ® 56 ribavirin therapy 56 Jevtana 56 Engerix B 56 #mg BID [002] 56 mCRPC 56 ipilimumab 56 anti leukemic 56 MADRS score 56 atazanavir ritonavir 56 EDEMA4 trial 56 secondary efficacy endpoint 56 NMIBC 56 oral allopurinol 56 goserelin 56 HBeAg positive 56 alemtuzumab treated 56 mg TID 56 relapsed multiple myeloma 56 colorectal liver metastases 56 CPOP R 56 MELD scores 56 HGS ETR2 56 histologically confirmed 56 low dose Iluvien 56 oral diclofenac 56 lopinavir r arm 56 EGFR TKI 56 relapsing remitting multiple sclerosis 56 rituximab refractory 56 ancrod 56 huN# DM1 56 exemestane 56 IV NSCLC 56 stage IIIb 56 sirolimus eluting stents 56 elagolix 56 paclitaxel eluting stents 56 seroprotection 56 irinotecan chemotherapy 56 undetectable HBV DNA 56 satraplatin Phase 56 dasatinib Sprycel ® 56 zoledronic acid 56 receiving highly emetogenic 56 mg dose 56 disease progression 56 baseline HbA1c 56 Abiraterone Acetate 56 pegylated interferon alfa 56 SCH # 56 severe neutropenia 56 p = #.# [002] 56 allogeneic SCT 56 REYATAZ r 56 Tarceva TM 56 epirubicin 56 discontinuations due 56 HGS ETR1 56 refractory CLL 56 statistically significant improvement 56 nonfatal myocardial infarction 56 MGd 56 trastuzumab Herceptin R 56 CYPHER R Stent 55 nilotinib 55 androgen independent 55 imetelstat 55 CHOP chemotherapy 55 Zometa hazard 55 relapsed myeloma 55 splenectomized 55 chemoradiation therapy 55 metastatic CRPC 55 dose cytarabine 55 unresectable stage 55 recurrent VTE 55 mcg QD 55 active comparator 55 cytoreduction 55 non metastatic osteosarcoma 55 lymphoma CTCL 55 panitumumab 55 ofatumumab 55 advanced hepatocellular carcinoma 55 highly emetogenic 55 tumor regression 55 gastrointestinal stromal tumor GIST 55 fulvestrant 55 Rate ORR 55 #mg QD [001] 55 tolerability 55 blinatumomab 55 interferon gamma 1b 55 Raptiva r 55 DMARDs 55 primary patency 55 TAXUS Liberte Long 55 cytarabine 55 Vectibix monotherapy 55 CLARITY study 55 reinfarction 55 abacavir lamivudine 55 doxorubicin 55 interferon alfa 2b 55 statistically significant p = 55 CoFactor 55 eculizumab 55 AVADO 55 irinotecan 55 Taxotere R 55 EBMT criteria 55 nitazoxanide 55 MCyR 55 Aptivus ® 55 neoadjuvant treatment 55 etoposide 55 iniparib 55 antiretroviral naive 55 entecavir 55 pertuzumab 55 plus prednisone prednisolone 55 achieved statistical significance 55 Sustained virologic response 55 pharmacodynamic PD 55 androgen suppression 55 celgosivir 55 GvHD 55 TAXUS Stent 55 plasma HCV RNA 55 dexamethasone 55 ACR# responses 55 operable breast cancer 55 pioglitazone 55 plus OBT 55 unfractionated heparin 55 univariate analysis 55 PEGylated Fab fragment 55 Tavocept 55 log# IU mL 55 placebo 55 bone metastases 55 dosing cohort 55 pegylated interferon alfa 2a 55 febrile neutropenia 55 abatacept 55 prednisone prednisolone plus 55 PSA nadir 55 stage IIIB IV 55 recurrent GBM patients 55 lymph node metastases 55 Cytoxan 55 CANCIDAS 55 INCB# [001] 55 Kaplan Meier 55 leukemia CLL 55 oxycodone CR 55 PROVENGE 55 IRESSA 55 cyclophosphamide FC 55 Partial Response 55 pazopanib 55 binary restenosis 55 tirofiban 55 adjuvant radiation 55 acute STEMI 55 PREZISTA rtv 55 angiographic outcomes 55 MACCE 55 clinically meaningful 55 pT3 55 Timed Walk 55 virological response 55 androgen deprivation 55 Aflibercept 55 CALGB # [002] 55 follicular lymphoma 55 relapsed MCL 55 ER CHOP 55 HIV RNA 55 liposomal doxorubicin 55 FEMALES SHOULD BE ADVISED 55 octreotide 55 adjuvant cisplatin 55 forodesine 55 APTIVUS 55 metastatic pancreatic 55 autologous stem cell 55 serum clusterin levels 55 RG# [001] 55 ULORIC 55 nonresponders 55 PEG IFN 55 comparator PI r 55 Psoriasis Area 55 follicular lymphomas 55 Index CDAI 55 cyclophosphamide 55 VIDAZA azacitidine 55 underwent surgical resection 55 chronic angina 55 docetaxel pretreated 55 daily Infergen 55 tolerability profile 55 metastatic malignant 55 unresectable locally advanced 55 fibrinolytic therapy 55 genotypic resistance 55 TAXUS V 55 autoantibody positive 55 IIIa inhibitor 55 letrozole 55 primary efficacy endpoints 55 multicenter Phase 55 refractory chronic lymphocytic 55 evaluating REVLIMID 55 receiving golimumab 54 advanced adenoma 54 serum urate 54 HUMIRA achieved PASI 54 evaluating tivozanib 54 copies mL 54 PROVENGE ® 54 invasive aspergillosis 54 TO AVOID PREGNANCY WHILE 54 lapatinib 54 alteplase 54 postmenopausal osteoporotic women 54 lamivudine refractory patients 54 antiretroviral naïve 54 fosamprenavir 54 demonstrated statistically significant 54 Teriflunomide 54 median survivals 54 T DM1 54 unblinded 54 FOLPI regimen 54 clopidogrel 54 log# copies mL 54 evaluating Xcytrin 54 DOXIL 54 demonstrated clinically meaningful 54 mg m² 54 p = NS 54 rosuvastatin #mg 54 placebo PBO 54 non squamous NSCLC 54 AVASTIN 54 cisplatin gemcitabine 54 metastatic hormone refractory 54 TMC# C# 54 retinal thickness 54 serum HCV RNA 54 thromboembolic events 54 PEG interferon 54 HCV infected 54 L MTP PE 54 adult chronic ITP 54 KRAS mutations 54 TMC# r 54 EGFR mutations 54 anthracycline taxane 54 5 Fluorouracil 54 BARACLUDE ® 54 resectable 54 taxane therapy 54 REMICADE ® 54 Lenalidomide 54 recurrent malignant glioma 54 prostate cancer HRPC 54 response pCR 54 mg doses 54 doripenem 54 vicriviroc 54 GnRH agonist 54 elotuzumab 54 seliciclib 54 EVEREST II 54 fluoropyrimidine 54 xenograft models 54 NEVO ™ 54 Pegasys plus Copegus 54 GVAX 54 vidofludimus 54 lumiliximab 54 tanespimycin 54 target vessel revascularization 54 TAXUS VI 54 peginterferon alfa 2a #KD 54 alicaforsen enema 54 PegIntron 54 mcg BID 54 ATACAND 54 elacytarabine 54 tapentadol ER 54 ACTEMRA 54 COPEGUS 54 Xanafide 54 taxane chemotherapy 54 patients receiving ERBITUX 54 methotrexate 54 Newly Diagnosed Multiple Myeloma 54 bortezomib Velcade R 54 mg/m2 administered 54 radical nephrectomy 54 IV malignant melanoma 54 systemically administered 54 renal function 54 Xcytrin 54 TYKERB 54 Lupuzor ™ 54 clinical trials Multikine 54 adjunctive placebo 54 insulin glargine 54 cyclophosphamide doxorubicin vincristine 54 double blinded randomized 54 HSCT 54 Phase Ib study 54 DASISION 54 receiving INTRON 54 refractory indolent non 54 interferon ribavirin 54 diameter stenosis 54 CYPHER Stent 54 adriamycin 54 CDAI 54 unresectable tumors 54 peg interferon 54 ZOLINZA 54 Gemzar ® 54 Fibrillex TM 54 nucleoside naive 54 serologically active patients 54 oral rivaroxaban 54 anti TNF 54 ximelagatran 54 subcutaneously administered 54 hours postdose 54 SUTENT 54 concurrent chemoradiation 54 relapsing MS 54 oral chemotherapeutic agent 54 Irinotecan 54 small lymphocytic lymphoma 54 HDRS 54 COPEGUS ribavirin 54 placebo p 54 Gemcitabine 54 PROMACTA 54 histologic 54 K ras mutations 54 EOquin TM 54 metastatic pancreatic cancer 54 diagnosed GBM 54 leucovorin 54 metastatic castrate resistant 54 mg qd 54 bone metastasis 54 regorafenib 54 dose regimens 54 ARCOXIA 54 atheroma volume 54 virologic responses 54 BRIM3 54 aflibercept 54 assessing T DM1 54 TNFerade 54 postoperative mortality 54 refractory acute myeloid 54 FTY# 54 palifosfamide 54 Navelbine 54 NATRECOR ® 54 confidence interval #.#-#.# 54 ritonavir boosted 54 WBRT 54 mg administered orally 54 Mylotarg 54 underwent resection 54 5 FU leucovorin 54 treatment naïve genotype 54 Dacogen injection 54 TTF Therapy 54 dexamethasone Decadron 54 DTIC 54 Xeloda ® 54 Traficet EN 54 Primary endpoints 54 % CI #.#-#.# [005] 54 virus HCV protease inhibitor 54 dose escalation phase 54 pain palliation 54 ELACYT 54 Neoadjuvant 54 prognostic variables 54 ara C 54 darunavir ritonavir 54 #mg/day [001] 54 carboplatin chemotherapy 54 subcutaneous PRO 54 chemo radiotherapy 54 mg d 54 ABC/3TC 54 undetectable virus HCV 54 HER2 positive breast cancer 54 MitraClip device 54 chemotherapy docetaxel 54 Trastuzumab 53 ipsilateral stroke 53 sUA 53 PCa 53 levofloxacin 53 previously untreated follicular 53 doxorubicin docetaxel 53 randomized discontinuation trial 53 pharmacodynamic 53 administered subcutaneously 53 capecitabine Xeloda 53 immunomodulatory therapy 53 oral clodronate 53 receiving prophylactic anticoagulation 53 denufosol 53 radiographic progression 53 Cloretazine 53 plus COPEGUS 53 perioperative mortality 53 Bevacizumab 53 icatibant 53 unfractionated heparin UFH 53 phase IIb clinical 53 candesartan 53 EGFR mutation 53 Tamibarotene 53 Fludarabine 53 clinically meaningful improvement 53 DAS# CRP 53 cytoreductive nephrectomy 53 radical cystectomy 53 intermittent dosing 53 oxaliplatin Eloxatin 53 sorafenib tablets 53 malignant pleural mesothelioma 53 mg kg 53 iclaprim 53 Pemetrexed 53 virological failure 53 recurrent glioblastoma 53 chronic HCV infection 53 copies ml 53 R0 resection 53 oral Xeloda 53 prostate cancer mCRPC 53 AIR CF1 53 hypercalcemia 53 angiographic restenosis 53 target lesion revascularization 53 pegylated interferon peg IFN 53 HCV SPRINT 53 huC# DM4 53 CLL SLL 53 Alocrest 53 multicentre randomized 53 ABVD 53 doxorubicin HCl liposome injection 53 docetaxel Taxotere R 53 metastatic colorectal carcinoma 53 prior nephrectomy 53 cytokine refractory 53 ASCT 53 adjuvant radiotherapy 53 rosuvastatin 53 ErbB2 positive 53 GOUT 53 Sustained Virological Response 53 nondiabetic patients 53 sapacitabine 53 ARIMIDEX 53 LPV r 53 gout flares 53 oral FTY# 53 Montgomery Asberg Depression 53 follicular non 53 REYATAZ r arm 53 randomized multicenter Phase III 53 mcg kg REBETOL 53 mg/m2/day 53 mcg Albuferon 53 divalproex sodium 53 Telintra 53 μg dose 53 migalastat HCl 53 nucleoside naive patients 53 clopidogrel Plavix 53 paclitaxel 53 imatinib resistant 53 TMC# [001] 53 iniparib BSI 53 Pharmacokinetic parameters 53 insulin detemir 53 vincristine doxorubicin 53 abciximab 53 bevacizumab Avastin 53 tumor xenograft models 53 Hazard Ratio HR 53 carfilzomib 53 HORIZONS AMI trial 53 randomized Phase 2b 53 gp# vaccine 53 metastatic lung cancer 53 Phase Ib clinical 53 TAXUS stent 53 CsA 53 DAS# [002] 53 chemotherapy cisplatin 53 ACR# ACR# 53 refractory HL 53 care regimens CCR 53 ACZ# 53 Kaplan Meier method 53 tamsulosin 53 cilostazol 53 cytarabine daunorubicin 53 hepatitis C genotype 53 dose escalation 53 olaparib 53 pancreatic neuroendocrine tumors 53 iodixanol 53 PegIFN 53 paclitaxel cisplatin 53 doxorubicin cyclophosphamide 53 microbiologically evaluable 53 Cloretazine ® 53 ug kg 53 recurrent metastatic 53 log# reduction 53 efficacy endpoint 53 Aromasin 53 enzastaurin 53 bivalirudin 53 tesmilifene 53 BCIRG 53 CDAI score 53 vismodegib 53 systemic embolism 53 null responder HCV 53 ulcerative colitis UC 53 pneumonectomy 53 non squamous histology 53 thymoma 53 log# 53 INC# 53 NovoTTF